High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). (Q33375798)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Wolfgang Hiddemann

12

object named as

Wolfgang Hiddemann

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Dreyling

13

object named as

Martin Dreyling

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Unterhalt

11

object named as

Michael Unterhalt

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Rudolf Weide

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Georg Hess

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hubert Köppler

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jochen Heymanns

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jörg Thomalla

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ali Aldaoud

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christoph Losem

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stefan Schmitz

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ursula Haak

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christoph Huber

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

German Low Grade Lymphoma Study Group

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1299-1306

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Identifiers

10.1080/10428190701361828

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33375798&oldid=2092777207"